Kjell G. Stenberg, CEO of Cyxone, commented: "I have very strong belief in the projects and that our candidates may change the future treatments for MS and rheumatoid arthritis. I think this is just the beginning of our journey and I see this as a great opportunity for me to expand my personal holdings in the company at a good price."

CEO Kjell G. Stenberg also previously expanded his private holdings in Cyxone on August 29, 2019, when he acquired 8,811 shares at a price of 6.81 SEK for the total value of 60,000 SEK.

Contact
Cyxone AB (publ)
Kjell G. Stenberg, CEO
Phone: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden

About Cyxone
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company's drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typically associated with various immune-related disorders. Cyxone's technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone's Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, ca@mangold.se.www.cyxone.com